Healthscope exits GP market, boosts tech investment in pathology

Private hospital and pathology laboratory operator Healthscope has reported a decline in net profit of almost 40 per cent for the 2017 financial year, mainly due to a write-down from the sale of its 43-strong medical centre portfolio, but the company says it will continue to invest in infrastructure and technology.

The ASX-listed multinational's new CEO, former Telstra executive Gordon Ballantyne, highlighted the New Zealand pathology division as a bright spot with increased investment in technology leading to efficiency gains, but said the hospital division was suffering from soft market conditions.

Posted in Australian eHealth

Tags: HealthLink, Sysmex, Healthscope

You need to log in to post comments. If you don't have a Pulse+IT website account, click here to subscribe.

Sign up for Pulse+IT eNewsletters

Sign up for Pulse+IT website access

For more information, click here.

Copyright © 2021 Pulse+IT Communications Pty Ltd
No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher.
Supported by Social Media Agency | pepperit